BioSpace News Archive

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced the appointment of Neil Gallagher, M.D., Ph.D., to the role of President, Head of Research and Development (R&D), effective April 10, 2023.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive first-in-human pharmacokinetic and hematology data from its Phase 1a single and multiple ascending dose trial for its investigational novel BET inhibitor, VYN201.

IMUNON, Inc. announced financial results for the year ended December 31, 2022, and provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer.

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the year ended December 31, 2022 and provided a corporate update.

RedHill Biopharma Ltd. announced that it has entered into a definitive agreement for the purchase and sale of 1,500,000 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, series A warrants to purchase up to an aggregate of 1,500,000 ADSs and series B warrants to purchase up to an aggregate of 1,500,000 ADSs at a purchase price of $4.00 per ADS and associated warrants, in a registered direct offering.

Valneva SE, a specialty vaccine company, announced it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable on Zika vaccines next week at the 23rd World Vaccine Congress in Washington, D.C.

Sanofi announced that its Q1 2023 Memorandum for modelling purposes is available on the “Investors” page of the company’s website.

Hansa Biopharma AB “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced the release of the Annual Report 2022.

Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision microbiome oncology therapeutics, announced the successful closing of a US $3 million equity investment by Chartered Group, a well-established global private investment group.

Bioretec Ltd. has received market authorization for its RemeOs™ trauma screw in the U.S. The RemeOs™ trauma screw is the first and currently only bioresorbable metal implant approved by the U.S. Food and Drug Administration.